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a  b  s  t  r  a  c  t
Rheumatoid arthritis (RA) is an autoimmune inﬂammatory rheumatic disease which affects
several organs and tissue, predominantly the synovial joints. Like many other autoimmune
diseases, RA is a complex disease, where genetic variants, environmental factors and ran-
dom events interact to trigger pathological pathways. Genetic implication in RA is evident,
and  recent advances have expanded our knowledge about the genetic factors that contribute
to  RA. An exponential increment in the number of genes associated with the disease has
been described, mainly through gene wide screen studies (GWAS) involving international
consortia with large patient cohorts. However, there are a few studies on Latin American
populations. This article describes what is known about the RA genetics, the future that is
emerging, and how this will develop a more personalized approach for the treatment of the
disease. Latin American RA patients cannot be excluded from this ﬁnal aim, and a higher
collaboration with the international consortia may be needed for a better knowledge of the
genetic proﬁle of patients from this origin.
© 2015 Elsevier Editora Ltda. All rights reserved.
Genética  da  artrite  reumatoide:  é  necessário  um  novo  impulso  em
populac¸ões  latino-americanas
alavras-chave:
rtrite reumatoide
LA
r  e  s  u  m  o
A artrite reumatoide (AR) é uma doenc¸a reumática inﬂamatória autoimune que afeta
vários órgãos e tecidos, predominantemente as articulac¸ões sinoviais. Como muitas out-
ras  doenc¸as autoimunes, a AR é uma doenc¸a complexa, em que variantes genéticas, fatores
studo de associac¸ão genômica
mpla
usceptibilidade genética
olimorﬁsmo de nucleotídeo único
ambientais e eventos aleatórios interagem e desencadeiam vias patológicas. A implicac¸ão
genética na AR é evidente e avanc¸os recentes têm expandido nosso conhecimento sobre
os  fatores genéticos que contribuem para a doenc¸a. Houve um incremento exponencial
na quantidade de genes associados à doenc¸a descritos, principalmente por estudos de
associac¸ão  genômica ampla (GWAS) que envolveram consórcios internacionais com grandes
∗ Corresponding author.
E-mail: rdiazp@uautonoma.cl (R. Díaz-Pen˜a).
ttp://dx.doi.org/10.1016/j.rbre.2015.10.004
255-5021/© 2015 Elsevier Editora Ltda. All rights reserved.
172  r e v b r a s r e u m a t o l . 2 0 1 6;5 6(2):171–177
grupos de pacientes. No entanto, há poucos estudos em populac¸ões latino-americanas.
Este artigo descreve o que é conhecido sobre a genética na AR, o que vem a seguir e como
isso vai desenvolver uma abordagem mais personalizada para o tratamento da doenc¸a. Os
pacientes latino-americanos com AR não podem ser excluídos desse objetivo ﬁnal e pode
ser  necessária uma maior colaborac¸ão com os consórcios internacionais para se obter um
melhor conhecimento do perﬁl genético dos pacientes provenientes dessa região.
©  2015 Elsevier Editora Ltda. Todos os direitos reservados.Rheumatoid  arthritis
Rheumatoid arthritis (RA) is an autoimmune inﬂammatory
rheumatic disease that affects many  tissues and organs,
mainly synovial joints. This disease leads to progressive
destruction of articular cartilage and ankylosis of the joints.1
Subsequent, pannus formation may lead to destruction of
underlying cartilage and bony erosions. RA diagnosis is based
on clinical criteria and laboratory tests.2 Anti-citrullinated
protein autoantibodies (ACPA) show a high speciﬁcity for RA,
even ACPA testing has become a substantial component of the
current American College of Rheumatology (ACR)-European
League Against Rheumatism (EULAR) classiﬁcation criteria for
RA.3 Additionally, it has been described that ACPA may play a
role in disease pathogenesis.4
RA affects approximately 1% of the population worldwide.5
In the last years, several epidemiological studies of RA have
been published, showing variations in the incidence and
prevalence of RA across populations. Most of the studies have
been developed in countries from the North Europe and North
America, estimating prevalences of 0.5–1.1%.5 Another stud-
ies made mainly in countries from South Europe reported a
lower prevalence around 0.3–0.7%.6–8 The lowest prevalence
data have been reported in areas from Africa and Asia, and the
highest in Native American populations.5 In fact, the preva-
lence of RA is 10 times higher among Canadian or Native
Americans than Europeans (3% and 0.3%, respectively).9,10
Although the disease can develop at any age, RA affects
females more  frequently than males and it is diagnosed
mainly in age 40–60 years, although the mechanism by which
gender inﬂuences the susceptibility to RA remains unclear.
Other characteristic of RA is heterogeneity: patients do not
form a homogenous population and some clinical RA sub-
groups, such as ACPA seropositive versus seronegative, erosive
versus non-erosive, progressive versus mild-course, have been
identiﬁed.11–13
RA  genetics  and  pathogenesis
Like many  autoimmune diseases, the etiology of RA is
multifactorial. Genetic susceptibility is evident in familial
clustering and monozygotic twin studies, with a 50% of RA
risk attributable to genetic factors, and heritability of RA
4has been estimated to be about 60%. Moreover, disease
progression, outcome and RA phenotype have been asso-
ciated with genetic factors.11,14,15 Thus, understanding the
genetics basis of RA is required in order to develop a morepersonalized approach for the disease treatment. RA genetic
risk factors can be classiﬁed into two groups: (1) major
histocompatibility complex (MHC) genes and (2) non-MHC
regions. Interestingly, HLA and some non-HLA genes have
been linked to the development of antibodies against cit-
rullinated proteins, differentiating between two entities with
distinctive characteristics, ACPA seropositive and seronega-
tive RA.16 Interestingly, several genetic polymorphisms have
been described associated to environmental factors in RA
patients, primarily smoking.17 Smoking and possibly other
environmental factors may trigger ACPA production and the
development of ACPA seropositive RA (Fig. 1).11,16 Although
the etiology of RA has not been elucidated yet, their symptoms
develop gradually in different phases.18 In this development of
the disease has been described a “preclinical phase”, in which
several immunological markers, as ACPA or rheumatoid factor
(RF), become positive sometimes years before of the onset of
clinical symptoms. To sum up, RA develops in genetically pre-
disposed individuals subjected to an unclear set of life events,
specially smoking (Fig. 1).
HLA  region
The genomic map  of the human MHC (HLA) spans about 7.6 Mb
and contains approximately 421 gene loci on a contiguous
region on chromosome 6.19 The classical HLA loci, which play
a central role in the immune system, are called -A, -B, and -C
(class I) and -DRB1, -DQB1, and -DPB1 (class II). Particularly,
the HLA class I and class II genes encode for proteins that
bind to small antigen peptides and carry them into the cell
surface thus presenting them to the immune system. There-
fore, this genomic region is crucial for the organism resistance
and susceptibility to pathogenic factors.
It has been 35 years since it was published that the HLA
region contributes to RA susceptibility, speciﬁcally HLA-DR4
allele,20 but the exact mechanism that determines the predis-
position is unknown. Among the HLA genes, the HLA-DRB1
shared epitope (SE) alleles that encode for a common amino
acid sequence, is the most important risk factor described for
RA susceptibility and progression.21 The presence of SE sug-
gest that the HLA alleles containing it bind the same antigen,
postulating the presentation of arthritogenic self-peptides or
molecular mimicry with foreign antigens,22,23 and/or shap-
ing the T-cell-antigen repertoire.24 HLA-DRB1 SE alleles are
strongly associated with ACPA-positive RA. Indeed, HLA-DRB1
SE alleles contribute in 18% to the heritability of ACPA-positive
RA, whereas they only contribute in 2.4% to the heritability of
ACPA-negative RA.25 The relationship between HLA-DRB1 SE
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Fig. 1 – Hypothetical model for initiation of RA in ACPA-positive individuals. In an induction phase, environmental factors
could contribute to stimulate the innate immunity. Apoptosis, necrosis, or both of some cells could cause citrullination in
certain proteins in the lungs (due to the increase in the activity of peptidylarginine deiminases enzymes, PAD). Some of
these modiﬁed proteins bind speciﬁcally to HLA-DR molecules on dendritic cells or macrophages resulting in high titers of
ACPA. Citrullination proteins in the joints due to infection, trauma, exercise, etc., could lead to immune complex formation
between modiﬁed proteins and ACPA, which further bind to Fc receptors on the surface of synovial macrophages,
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tontributing to the perpetuation of inﬂammation.
nd ACPA in the pathogenesis of RA has been explained by cit-
ullinated peptide binding into the pocket of DRB1 molecules
ontaining the shared epitope, and the consequent activa-
ion of CD4+ T cells and polarization to Th17 cells, a Th
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populations (35.8%).26,27 In ACPA-positive RA patients, 80%
have at least one SE, while 49% of ACPA-negative RA patients
have SE. This interaction among genetic risk factors and the
presence of autoantibodies increase the risk of developing RA
in ﬁrst-degree relatives of RA patients.27,28
The SE hypothesis remains controversial, because sug-
gest the existence of an autoantigenic peptide that has
not identiﬁed yet. Several other diseases, like Type I dia-
betes, psoriatic arthritis, lupus, early-onset chronic lymphoid
leukemia, and other conditions,29 and this promiscuity are
incongruous with tenets of MHC-restricted antigen pre-
sentation theory. Although HLA-DRB1 alleles containing
the epitope are established genetic risk factors in RA,
the precise immunological implications of their expres-
sion are not clear. Furthermore, it has been reported that
shared epitope alleles at the HLA-DRB1 locus do not com-
pletely explain the association of the MHC  region with the
disease.30–32
Non-HLA  genetic  associations
The pathogenesis of RA has a polygenic basis. About 50% of
RA risk is thought to be genetic and one-third of this risk
belongs to the HLA locus.4 Thus, genetic variation can be
explained by RA risk alleles in non-HLA locus. There has been
an exponential increase in the number of genes associated
with RA in the last several years, as shown in Fig. 2. Speciﬁ-
cally, in addition to the HLA-DRB locus, over 46 non-HLA RA
risk loci have emerged from genome-wide association stud-
ies (GWAS) and subsequent GWAS meta-analysis of GWAS
datasets,33,34 all of them in individuals of European ances-
try. Another meta-analysis of GWAS in Japanese population
was reported, which identiﬁed nine novel loci associated with
RA.35 The cited study provided evidence of signiﬁcant over-
lap in the RA genetic risks between Japanese and European
population, contributing to further understanding of the RA
etiology. GWAS are considered to be one of the primary tools
for determining genetic links to diseases. These analyses
have been abundant in recent scientiﬁc researches. In each
of these studies at least 100,000 single nucleotide polymor-
phisms (SNPs) are genotyped, taking an unbiased view of
the whole genome and therefore have a higher probability
of detecting an association with a genetic marker, provid-
ing the studies with sufﬁcient power. Fig. 2 captures the top
regions of RA associations that are statistically signiﬁcant. A
recent study discovered 42 novel RA risk loci at a genome-wide
level of signiﬁcance, bringing the total to 101.36 These study
genotyped around 10 million SNPs on a total of over 100,000
subjects of European and Asian ancestry, 29,880 RA patients
and 73,758 controls. In summary, the researchers were able
to establish 98 genes that could potentially contribute to the
onset of RA. Many  of these genes also play a role in other
diseases, including human primary immunodeﬁciency dis-
orders and blood cancers. They discovered many  genes that
overlap to contribute to the condition that are already being
targeted by existing drugs, but was not known when the drugs
were developed. This study provides evidences that genetic
of diseases could contribute to biological insight and drug
discovery. 0 1 6;5 6(2):171–177
Situation  in  Latin  American  populations
The study of genetics in Latin American populations is not
a trivial topic. The expression of genetic variants is mod-
iﬁed by many  environmental factors, and the signiﬁcance
of ethnicity in genetics is controversial.37 Latin Americans
have been wrongly designated as “Hispanics” and consid-
ered homogenous. Actually, the origins and destinations of
non-Amerindian populations have depended on the time and
reasons for the migration, and the degree of admixture varies
between Latin American countries according to the major
ancestry population component.38
There are important challenges in ﬁnding susceptibility
genes for RA in these populations. The Hispanic community is
an admixed population, and the allelic frequency differences
across ethnic groups can interfere with association studies
and lead to false-positive results. Thus, in GWAS, candidate
genes and replication studies of GWAS, differences found in
the allele frequencies may be originated more  by differences
in the populations structure than by the phenotype of the
disease. However, there are approaches to overcoming the
problem of population structure, like to use ancestry infor-
mative markers (AIMs),39 or include structured association
test (structure) and principal component analysis for adjusting
population stratiﬁcations in the studies.40,41
Although a high progress has been made in detecting the
genes implicated in RA susceptibility, little is known about
genetic susceptibility in the “Hispanic” populations of the
Americas. This is largely due to the difﬁculty of perform-
ing association studies in admixed populations and the fact
that the power required to identify genetic associations in
these populations is greater than in more  homogeneous popu-
lations. Some AR association studies have been previously
reported in Amerindian and mixed Hispanic populations, and
the strongest association observed was in the HLA class II
region. Speciﬁcally, genetic associations of RA with HLA-DRB1
alleles have been reported in Native Americans, Mexican
American ancestry, Colombian population, Chilean popula-
tion, Peruvian population, Brazilian population and Mexican
Mestizo population with a larger proportion of European
ancestry.42–48 A meta-analysis carried out across Latin Ameri-
can populations estimated the relevance of HLA-DRB1 alleles
on RA susceptibility, conﬁrming a signiﬁcant association
between RA and HLA-DRB1 gene and revalidating the shared
epitope hypothesis in Latin American populations.49 A recent
study examined susceptibility loci for RA in Latin American
individuals with admixed European and Amerindian genetic
ancestry.50 These study genotyped 196.524 markers, covering
the previously associated loci with various autoimmune dis-
eases, in 1.475 RA patients and 1.213 controls. A strong genetic
association of RA with the MHC region was observed, with
three independent effects, probably due to the diverse origin
of the samples. In the same study,50 RA associations previously
reported in GWAS (European and Asian populations) were
found, but with moderate signiﬁcant values (including STAT4,
IRF5, IL2RA, SPRED2, CCL21 and PTPN22 genes). Additionally,
two novel putative associations in ENOX1 gene on chromo-
some 13 and NNA25 gene on chromosome 12 were identiﬁed.
The results of this large-scale association study provided new
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erspectives into the RA genetic basis in Latin-Americans
ndividuals. Several of these ﬁndings require replication and
upply an impetus for future studies. Moreover, they provide
nteresting conclusions of the observed complexity of RA asso-
iations with HLA region, probably as a consequence of the
rigin diversity.
Genetic analyses undertaken in the recent years have
evealed a new picture for RA pathogenesis and made us aware
f heterogeneity among individuals and populations.
Genomics research is advancing rapidly, through SNP geno-
yping and the next genome sequencing, two techniques that
re improving our understanding of the RA etiopathogene-
is. The ﬁnal goal in the coming years is to identify genetic
ariants involved in the different clinical manifestations and
A-associated features, and thereby predict the evolution of
he disease, and ﬁnally, to establish new treatments for RA
ased on the prognosis of individuals, enabling the develop-
ent of personalized therapies for RA. Other aspects such as
pigenetics and pharmacogenetics,51,52 require further inves-
igation in order to establish any role they may have in RA.
egarding this last point, the ﬁnal objective of pharmacoge-
etics in rheumatology is to deﬁne genetically distinct patient
ubsets, which have differential responses to the various ther-
pies used to treat rheumatic diseases. A vast growing body
f literature describes the pharmacogenetics of drugs used in
A treatment.52–54 However, there are no data about RA phar-
acogenetic in Latin-American populations.
Variations in the frequency of certain genotypes across eth-
ic groups may occur, and due to this, genetic association
tudies conducted in Latin American must have a powerful
control population”. The large and diverse population of Latin
merica is a powerful resource for elucidating the genetic
asis of complex traits as RA.55
onclusions
ulticentric studies have shown a high relevance in the under-
tanding of the risk genetic factors in complex diseases.
herefore, an additional effort in the search for unknown
enetic predispositions and clarify differences in roles among
thnic groups, including Latin American populations, is
eeded. Investigation in genomics area has advanced very
uickly through SNPs genotyping and GWAS, and will advance
ven more  with the new massive sequencing techniques. In
his way, a better knowledge about genetic basis of RA in Latin
merican populations undoubtedly would contribute to a bet-
er understanding of this disease pathology.
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